InvestorsHub Logo

DewDiligence

03/05/20 8:13 AM

#228941 RE: DewDiligence #228599

ABUS 4Q19 results—12/31/19 pro forma cash=$103.1M—including $12.3M from use of ATM facility during 1Q20 to date:

https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-reports-fourth-quarter-and-year-end-2019-financial

2020 cash-burn guidance is $54-58M.

mick

03/23/20 9:32 PM

#229646 RE: DewDiligence #228599

reading $ABUS
RE;
ABUS kills another HBV compound—AB-452, an oral RNA destabilizer—due to safety problem:

https://www.globenewswire.com/news-release/2020/02/10/1982301/0/en/Arbutus-Announces-Decision-to-Discontinue-AB-452-and-to-Pursue-Development-of-a-Next-Generation-HBV-Specific-Oral-RNA-Destabilizer.html

Quote:
In October 2018, Arbutus announced its decision to delay the initiation of a planned 28-day Phase 1a/1b clinical trial for AB-452 in order to further evaluate the safety of the compound. This decision was based on findings in 90-day preclinical safety studies in two species. Since that time Arbutus has extensively reviewed and further characterized these preclinical findings, including repeating the 90-day safety studies.

Michael J. Sofia, Ph.D., Chief Scientific Officer of Arbutus, added, “After reviewing all the data from the preclinical studies, and in consultation with external regulatory and pre-clinical experts, we have decided to not move AB-452 forward.

This is second HBV compound ABUS has killed off in the past few months—in Oct 2019 ABUS terminated AB-506, a capsid inhibitor, due to a safety problem (#msg-151513575).

What’s left in ABUS’ pipeline? ABS-729, an injected RNA destabilizer, is in phase-1; and ABS-836 (the successor to the terminated AB-506), a capsid inhibitor*, is in preclinical development with phase-1 anticipated in 2021.

ABUS is down “only” 6% on today’s PR because it has been known for over a year that AB-452 had a safety issue.

--
*ENTA (#msg-153696410) and ASMB (#msg-148672065) are also developing an HBV capsid inhibitor (a/k/a “core” inhibitor or CpAM).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

DewDiligence

03/26/20 5:32 PM

#229877 RE: DewDiligence #228599

ABUS reports interim phase-1 data on AB-729 for HBV:

https://finance.yahoo.com/news/arbutus-announces-positive-preliminary-phase-200510591.html

AB-729 is an injected RNAi agent that targets HBsAg. The data reported today are from a single subcutaneous dose.

After 29 days, the mean reduction in HBsAg was: 0.2 logs in the 60mg cohort; and 0.8 logs in the 180mg cohort.

After 12 weeks, the mean reduction in HBsAg was: n/a in the 60mg cohort; and -1.0 logs in the 180mg cohort.

Whether HBsAg is the right target to be hitting is somewhat controversial—see, for instance, #msg-152274693.